ZJJF(SH:600668) Zhi Tong Cai Jing·2025-08-13 07:40Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the chemical raw material drug Vonoprazan Fumarate, which is a potassium ion competitive acid blocker used for treating gastroesophageal reflux disease [1] Company Summary - Jianfeng Group's subsidiary, Anhui Jianfeng Beika, has obtained the "Chemical Raw Material Drug Listing Application Approval Notice" for Vonoprazan Fumarate, with the notice number 2025YS00694 [1] - The approval signifies that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market [1] - The company has the necessary production line in place for Vonoprazan Fumarate, which will help expand the subsidiary's business scope [1] Industry Summary - Vonoprazan Fumarate is developed by Takeda Pharmaceutical Company Limited and is used for the treatment of reflux esophagitis [1] - The approval of this drug aligns with the growing demand for effective treatments in the gastroenterology sector, indicating potential market opportunities [1]